このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Inventiva バランスシートの健全性

財務の健全性基準チェック /06

Inventivaの総株主資本は€-32.0M 、総負債は€47.5Mで、負債比率は-148.3%となります。総資産と総負債はそれぞれ€69.6Mと€101.6Mです。

主要情報

-148.3%

負債資本比率

€47.52m

負債

インタレスト・カバレッジ・レシオ	n/a
現金	€27.34m
エクイティ	-€32.03m
負債合計	€101.59m
総資産	€69.56m

財務の健全性に関する最新情報

更新なし

Recent updates

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Feb 22

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Sep 21

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Jan 05

財務状況分析

短期負債: IVA これは、短期資産が短期負債をカバーできないことよりも深刻な状況である。

長期負債: IVA これは、短期資産が長期負債をカバーできないことよりも深刻な状況である。

デット・ツー・エクイティの歴史と分析

負債レベル: IVA は株主資本がマイナスであり、これは高い負債水準よりも深刻な状況である。

負債の削減: IVAの株主資本はマイナスであるため、負債が時間とともに減少しているかどうかを確認する必要はない。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: IVA は、現在のフリーキャッシュフローに基づくキャッシュランウェイが1年未満である。

キャッシュランウェイの予測: IVA フリー・キャッシュ・フローが毎年 %の過去のペースで減少し続ければ、キャッシュ・ランウェイは1年未満となる。20.3

Inventiva バランスシートの健全性

財務の健全性 基準チェック /06

主要情報

財務の健全性に関する最新情報

Recent updates

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022

Inventiva receives a €4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation

Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanifibranor

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $30.00001 million.

Inventiva Announces the Initiation of Its Pivotal Phase III Clinical trial Evaluating Lanifibranor in NASH

Inventiva Announces Collaboration on Non-Invasive Biomarkers to Identify Patients Responding to Lanifibranor with Regards to Nash Resolution and Fibrosis Improvement

Inventiva S.A. to Report First Half, 2021 Results on Sep 20, 2021

Inventiva Announces Design of Phase III Clinical Trial with Lanifibranor in NASH

Inventiva lays out trial design for late-stage lanifibranor study in NASH

Inventiva Announces the Publication in the Journal of Hepatology of New Pre-Clinical Data Showing the Beneficial Effects of Lanifibranor on Cirrhosis

Inventiva S.A. Receives Positive Fda Feedback to Advance Its Lead Drug Candidate Lanifibranor into Pivotal Phase Iii in Nash

Inventiva Announces Appointment of Michael Cooreman as Chief Medical Officer

Inventiva Receives Fda Fast Track Designation in Mps Vi for Its Clinical-Stage Asset Odiparci

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva S.A. to Present the Results of Its Native Phase IIb Clinical Trial with Lanifibranor in Nash During Plenary Session at the Liver Meeting Digital Experience™ 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /06